China-based Acotec Scientific Holdings Ltd (HKG: 6669) has announced receiving marketing approval from the National Medical Products Administration (NMPA) for its paclitaxel-coated arteriovenous fistula high-pressure balloon dilation catheter, ACOART AVENS. The product is intended for use in percutaneous transluminal angioplasty (PTA) for autologous arteriovenous fistula stenosis in hemodialysis patients.
Product Features and Applications
The ACOART AVENS catheter features optimized product coating and the use of new materials, enhancing its performance in addressing stenosis in autologous arteriovenous fistulas. This approval marks a significant advancement in the treatment options available to hemodialysis patients, offering a potential improvement in the management of vascular access complications.
Implications for Hemodialysis Patients
The introduction of ACOART AVENS aims to provide hemodialysis patients with a more effective treatment option for maintaining vascular access, which is crucial for the delivery of dialysis therapy. The product’s innovative design and material choices underscore Acotec Scientific’s commitment to advancing medical device technology.-Fineline Info & Tech
